Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | How can we enhance the efficacy of TILs therapy in solid tumors?

Paolo Ascierto • 23 Oct 2026
ESMO 2026
General GC101 Lifileucel

Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy, comments on the future of tumor-infiltrating lymphocytes (TILs) therapy, highlighting the need to improve specificity while maintaining polyclonality by selecting clones against specific antigens. Enhancing persistence and reducing toxicity, potentially through combinations with checkpoint inhibitors like PD-(L)1, or innovative strategies such as IL-23 or IL-15 engineering, are crucial steps forward. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Ascierto

MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
1:49
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026
What is the importance of CTLA-4 inhibition in treating melanoma?
1:05
What is the importance of CTLA-4 inhibition in treating melanoma?
Paolo Ascierto • 20 Oct 2025
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
2:55
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
Paolo Ascierto • 20 Oct 2025

Related Videos

Drug price competition and the potential for tendering in oncology care
1:34
Drug price competition and the potential for tendering in oncology care
Daniel Goldstein • 23 Oct 2026
What financial challenges patients and healthcare systems face in oncology?
1:11
What financial challenges patients and healthcare systems face in oncology?
Daniel Goldstein • 23 Oct 2026
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
1:49
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
Paolo Ascierto • 23 Oct 2026
Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals